Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pseudomonas aeruginosa injection (PA-MSHA) to prevent bile leakage after hepatectomy
ChiCTR2400088520Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of PA-MSHA in hepatic neoplasm, hepatolithiasis (HL) and hepatic echinococcosis (HE) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: bile leakage. Started Aug 2024; status: recruiting.
02
Drugs
PA-MSHA
03
Conditions
hepatic neoplasmhepatolithiasis (HL)hepatic echinococcosis (HE)
Beyond the preview
Go deeper on ChiCTR2400088520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088520.